Transcription of Guideline on stability testing for applications for ...
{{id}} {{{paragraph}}}
7 Westferry Circus Canary Wharf London E14 4HB United Kingdom An agency of the European Union Telephone +44 (0)20 7418 8400 Facsimile +44 (0)20 7418 8416 E-mail Website European Medicines Agency, 2014. Reproduction is authorised provided the source is acknowledged. 21 March 2014 EMA/CHMP/CVMP/QWP/441071/2011- Committee for Medicinal Products for Human Use (CHMP)/ Committee for Medicinal Products for Veterinary Use (CVMP) Guideline on stability testing for applications for variations to a marketing authorisation Draft Agreed by CHMP / CVMP Quality Working Party June 2011 Adoption by CHMP for release for consultation June 2011 Adoption by CVMP for release for consultation July 2011 End of consultation (deadline for comments) 31 January 2012 Agreed by QWP December 2013 Adoption by CHMP Feb
Where appropriate, the concept of bracketing and matrixing as described in the CHMP/ICH and the CVMP/VICH Note for Guidance on Bracketing and Matrixing Designs for Stability Testing of Drug Substances and Drug Products may be applied across related products.
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document:
{{id}} {{{paragraph}}}
ICH STABILITY REQUIREMENTS Overcoming the Challenges, Stability testing of New Drug Substances and Products, Stability testing, Testing of New Drug Substances and Products, Bracketing and Matrixing Designs for Stability Testing of New Drug Substances and Products, Stability, SUPAC GUIDELINES, Bracketing and matrixing designs for stability testing, Drug substances, Drug products, Testing, New drug